S C Auld1, B K Moore2, W P Killam3, B Eng3, K Nong3, E C Pevzner2, K K Eam4, M T Eang4, D Warren3, S J Whitehead5. 1. Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Division of TB Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 3. Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Phnom Penh, Cambodia. 4. National Center for Tuberculosis and Leprosy Control (CENAT), Phnom Penh, Cambodia. 5. Division of TB Elimination, Centers for Disease Control and Prevention, Nonthaburi, Thailand.
Abstract
OBJECTIVE: To describe the implementation and utilization of the Xpert (®) MTB/RIF (Xpert) assay to diagnose tuberculosis (TB) among people living with the human immunodeficiency virus/acquired immune-deficiency syndrome (HIV/AIDS, PLHA) in Cambodia. DESIGN: Following the rollout of Xpert, an evaluation was conducted in four provinces of Cambodia from March to December 2012 to determine the utilization, performance, and turnaround time (TAT) of Xpert among PLHA. Data were collected from paper-based patient registers. RESULTS: Of 497 PLHA with a positive TB symptom screen, 357 (72%) were tested with smear microscopy, and 250 (50%) with Xpert; 25 (10%) PLHA tested with Xpert were positive for TB and none were rifampicin-resistant. The utilization of Xpert increased from 23% to 75%, with a median TAT of 1 day. Across districts, utilization ranged from zero to 85%, while the TAT ranged from zero to 22 days. CONCLUSION: While early data show increasing utilization of Xpert for PLHA with a positive symptom screen, most patients underwent smear microscopy as an initial diagnostic test. Training delays and challenges associated with specimen referral may have contributed to variability in Xpert uptake and TAT, particularly for sites without onsite Xpert testing. Enhanced programmatic support, particularly for specimen referral and results reporting, may facilitate appropriate utilization.
OBJECTIVE: To describe the implementation and utilization of the Xpert (®) MTB/RIF (Xpert) assay to diagnose tuberculosis (TB) among people living with the human immunodeficiency virus/acquired immune-deficiency syndrome (HIV/AIDS, PLHA) in Cambodia. DESIGN: Following the rollout of Xpert, an evaluation was conducted in four provinces of Cambodia from March to December 2012 to determine the utilization, performance, and turnaround time (TAT) of Xpert among PLHA. Data were collected from paper-based patient registers. RESULTS: Of 497 PLHA with a positive TB symptom screen, 357 (72%) were tested with smear microscopy, and 250 (50%) with Xpert; 25 (10%) PLHA tested with Xpert were positive for TB and none were rifampicin-resistant. The utilization of Xpert increased from 23% to 75%, with a median TAT of 1 day. Across districts, utilization ranged from zero to 85%, while the TAT ranged from zero to 22 days. CONCLUSION: While early data show increasing utilization of Xpert for PLHA with a positive symptom screen, most patients underwent smear microscopy as an initial diagnostic test. Training delays and challenges associated with specimen referral may have contributed to variability in Xpert uptake and TAT, particularly for sites without onsite Xpert testing. Enhanced programmatic support, particularly for specimen referral and results reporting, may facilitate appropriate utilization.
Entities:
Keywords:
new diagnostics; performance; program evaluation; tuberculosis
Authors: Grant Theron; Lynn Zijenah; Duncan Chanda; Petra Clowes; Andrea Rachow; Maia Lesosky; Wilbert Bara; Stanley Mungofa; Madhukar Pai; Michael Hoelscher; David Dowdy; Alex Pym; Peter Mwaba; Peter Mason; Jonny Peter; Keertan Dheda Journal: Lancet Date: 2013-10-28 Impact factor: 79.321
Authors: Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins Journal: N Engl J Med Date: 2010-09-01 Impact factor: 91.245
Authors: Catharina C Boehme; Mark P Nicol; Pamela Nabeta; Joy S Michael; Eduardo Gotuzzo; Rasim Tahirli; Ma Tarcela Gler; Robert Blakemore; William Worodria; Christen Gray; Laurence Huang; Tatiana Caceres; Rafail Mehdiyev; Lawrence Raymond; Andrew Whitelaw; Kalaiselvan Sagadevan; Heather Alexander; Heidi Albert; Frank Cobelens; Helen Cox; David Alland; Mark D Perkins Journal: Lancet Date: 2011-04-18 Impact factor: 79.321
Authors: Anna Vassall; Sanne van Kampen; Hojoon Sohn; Joy S Michael; K R John; Saskia den Boon; J Lucian Davis; Andrew Whitelaw; Mark P Nicol; Maria Tarcela Gler; Anar Khaliqov; Carlos Zamudio; Mark D Perkins; Catharina C Boehme; Frank Cobelens Journal: PLoS Med Date: 2011-11-08 Impact factor: 11.069
Authors: Jacob Creswell; Andrew J Codlin; Emmanuel Andre; Mark A Micek; Ahmed Bedru; E Jane Carter; Rajendra-Prasad Yadav; Andrei Mosneaga; Bishwa Rai; Sayera Banu; Miranda Brouwer; Lucie Blok; Suvanand Sahu; Lucica Ditiu Journal: BMC Infect Dis Date: 2014-01-02 Impact factor: 3.090
Authors: Sarah Wood Pallas; Marissa Courey; Chhaily Hy; Wm Perry Killam; Dora Warren; Brittany Moore Journal: Appl Health Econ Health Policy Date: 2018-08 Impact factor: 2.561
Authors: Mariana Gaspar Botelho Funari de Faria; Rubia Laine de Paula Andrade; Ana Julia Gonçalves Camillo; Karina Fonseca de Souza Leite; Nanci Michele Saita; Valdes Roberto Bollela; Carlos Eduardo Menezes de Rezende; Aline Aparecida Monroe Journal: Rev Saude Publica Date: 2021-12-17 Impact factor: 2.106